We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Mereo BioPharma Group PLC | NASDAQ:MREO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.15 | 4.82% | 3.26 | 3.23 | 4.02 | 3.35 | 3.14 | 3.16 | 855,585 | 05:00:04 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of September, 2020
Commission File Number: 001-38452
MEREO BIOPHARMA GROUP PLC
(Translation of registrants name into English)
4th Floor, One Cavendish Place,
London, W1G 0QF, United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On September 29, 2020, Mereo BioPharma Group plc (the Company) issued a press release announcing the Companys financial results for the six months ended June 30, 2020. In addition, the Company is submitting with this Form 6-K its unaudited condensed consolidated financial statements as of June 30, 2020 and for the six months then ended.
Exhibit Index
Exhibits
99.1 | Press release, dated September 29, 2020, announcing the Companys financial results for the six months ended June 30, 2020. | |
99.2 | Unaudited condensed consolidated financial statements as of June 30, 2020 and for the six months then ended. | |
101 | Financial Statements, formatted in XBRL (eXtensible Business Reporting Language). |
The XBRL related information in Exhibit 101 to this Form 6-K shall not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section and shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.
The contents of this Report of Foreign Private Issuer on Form 6-K are incorporated by reference in the Companys registration statements on Form F-3 (File No. 333-239708), filed with the Securities and Exchange Commission (the SEC) on July 6, 2020, and on Form S-8 (File Nos. 333-236498 and 333-231636), filed with the SEC on February 18, 2020 and May 21, 2019, respectively.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: September 29, 2020
MEREO BIOPHARMA GROUP PLC | ||
By: |
/s/ Charles Sermon |
|
Name: Charles Sermon |
||
Title: General Counsel |
1 Year Mereo BioPharma Chart |
1 Month Mereo BioPharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions